Key result
A 600-mg clopidogrel loading dose reduces nonresponsiveness ~-mg during coronary stenting.
Why the study?
Limited information is available on the comparative effect of a 600-mg versus a 300-mg clopidogrel loading dose on nonresponsiveness and high post-treatment platelet aggregation in patients undergoing coronary stenting.
Does a 600-mg clopidogrel loading dose reduce nonresponsiveness and high post-treatment platelet aggregation compared to a 300-mg dose in patients undergoing coronary stenting?
RCT (n=190)
Does a 600-mg clopidogrel loading dose reduce nonresponsiveness and high post-treatment platelet aggregation compared to a 300-mg dose in patients undergoing coronary stenting?
Answers are grounded in this paper and cite their sources.
A 600-mg clopidogrel loading dose significantly reduces the incidence of nonresponsiveness and high post-treatment platelet aggregation compared to a standard 300-mg dose in patients undergoing coronary stenting.
OBJECTIVES: We determined the effect of clopidogrel dosing on the incidence of nonresponsiveness (NR) and high post-treatment platelet aggregation (post-PA). BACKGROUND: We have reported NR after a 300-mg loading dose. Limited information is available on the comparative effect of a 600-mg loading dose on the incidence of NR and high post-PA. METHODS: Clopidogrel responsiveness and post-PA were measured in patients undergoing stenting (n = 190) randomly treated with either a 300-mg or a 600-mg clopidogrel load. Nonresponsiveness was defined as <10% absolute change in platelet aggregation, and high post-PA was defined as >75th percentile aggregation after 300 mg clopidogrel. RESULTS: Nonresponsiveness was lower after 600 mg compared to the 300-mg dose (8% vs. 28% and 8% vs. 32% with 5 and 20 microM ADP, respectively, p < 0.001). Among the patients with high post-PA after 300 mg clopidogrel, 62% to 65% had NR, whereas after the 600-mg dose, all of the patients with high post-PA had NR. CONCLUSIONS: A 600-mg clopidogrel loading dose reduces the incidence of NR and high post-PA as compared to a 300-mg dose. Higher dosing strategies and methods to confirm platelet inhibition should be further investigated in order to optimally use clopidogrel in patients undergoing stenting.
No takes yet. Share an insight, caveat, or question.
Gurbel et al. (2005) conducted an RCT in Coronary stenting (n=190). Clopidogrel vs. 300-mg loading dose was evaluated on Nonresponsiveness (<10% absolute change in platelet aggregation) with 5 microM ADP (p=<0.001). A 600-mg clopidogrel loading dose reduced the incidence of nonresponsiveness compared to a 300-mg dose in patients undergoing coronary stenting.
Synapse has enriched 10 related papers. Consider them for comparative context: